Drug intelligence / Profile preview

IPL-699

Development stage: Preclinical
Lead developer: Immunity Pharma
Modality: Peptides

Overview

IPL-699 is a synthetic peptide drug candidate developed by Immunity Pharma Ltd. It is being investigated primarily for the treatment of neurodegenerative disorders, with a focus on amyotrophic lateral sclerosis (ALS). The drug is in preclinical development and has also been associated with potential applications in other nervous system diseases as well as endocrinology and metabolic diseases. Detailed information about its mechanism of action, specific molecular targets, or additional indications has not been disclosed publicly[1][8].

Beyond the preview

Go deeper on IPL-699.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IPL-699.

Explore the full profile